definiens: .(b ) When granted by [COMPANY] in this Supplement shall mean, with regard to Roche as theConducting Party, allowing the applicable Regulatory Authority in a country to have access to relevant information ( bycross - reference, incorporation by reference or otherwise ) contained in Regulatory Documentation ( and any datacontained therein ) filed with such Regulatory Authority with respect to [COMPANY] Compound ( and, in the case of Rocheas the Non - Conducting Party, the Right of Reference to the IND or the Combined Therapy IND ), only to the extentnecessary for the conduct of a Combined Therapy Trial in such country or as otherwise expressly permitted orrequired under the Agreement and/or this Supplement to enable Roche to exercise its rights or perform its obligationsunder the Agreement and/or this Supplement, and, except as to information contained in the IND or CombinedTherapy IND relating to the Combined Therapy, without the disclosure of such information to Roche